Cargando…

Sanger Sequencing for BRCA1 c.68_69del, BRCA1 c.5266dup and BRCA2 c.5946del Mutation Screen on Pap Smear Cytology Samples

Three sets of polymerase chain reaction (PCR) primers were designed for heminested PCR amplification of the target DNA fragments in the human genome which include the site of BRCA1 c.68_69del, BRCA1 c.5266dup and BRCA2 c.5946del respectively, to prepare the templates for direct Sanger sequencing scr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Sin Hang, Zhou, Shaoxia, Zhou, Tianjun, Hong, Guofan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4783961/ https://www.ncbi.nlm.nih.gov/pubmed/26867194 http://dx.doi.org/10.3390/ijms17020229

Ejemplares similares

Haplotypic characterization of BRCA1 c.5266dupC, the prevailing mutation in Brazilian hereditary breast/ovarian cancer
por: Gomes, Renan, et al.
Publicado: (2020)

The frequency of BRCA1 founder mutation c.5266dupC (5382insC) in breast cancer patients from Ukraine
por: Gorodetska, Ielizaveta, et al.
Publicado: (2015)

Polygenic Risk Score Predicts Modified Risk in BRCA1 Pathogenic Variant c.4035del and c.5266dup Carriers in Breast Cancer Patients
por: Berga-Švītiņa, Egija, et al.
Publicado: (2023)

BRCA1 c.68_69delAG (exon2), c.181T>G (exon5), c.798_799delTT and 943ins10 (exon11) mutations in Burkina Faso
por: Zoure, Abdou Azaque, et al.
Publicado: (2018)

Prevalence of the BRCA1 c.68_69delAG (BIC: 185delAG) mutation in women with breast cancer from north-central Poland and a review of the literature on other regions of the country
por: Hartwig, Martyna, et al.
Publicado: (2013)

Prevalence of the BRCA1 founder mutation c.5266dupin Brazilian individuals at-risk for the hereditary breast and ovarian cancer syndrome
por: Ewald, Ingrid P, et al.
Publicado: (2011)

Comparison of Targeted Next-Generation and Sanger Sequencing for the BRCA1 and BRCA2 Mutation Screening
por: Park, Joonhong, et al.
Publicado: (2016)

The Novel Pathogenic Mutation c.849dupT in BRCA2 Contributes to the Nonsense-Mediated mRNA Decay of BRCA2 in Familial Breast Cancer
por: Li, Sanrong, et al.
Publicado: (2018)

Mutation screening of BRCA1, BRCA2 and CHEK2*1100delC in Slovak HBOC families
por: Cierniková, S, et al.
Publicado: (2005)

Detecting the Frequency of c.5946delT Pathogenic Variant in the BRCA2 Gene and Associated Risk Factors Among Breast Cancer Patients Visiting Felege Hiwot Referral Hospital and University of Gondar Comprehensive Specialized Hospital
por: Berhane, Nega, et al.
Publicado: (2023)

Prevalence of 185delAG and 5382insC mutations in BRCA1, and 6174delT in BRCA2 in women of Ashkenazi Jewish origin in southern Brazil
por: Dillenburg, Crisle Vignol, et al.
Publicado: (2012)

BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2
por: Cline, Melissa S., et al.
Publicado: (2018)

Screening of BRCA1 (c.5177_5180delGAAA rs80357867 and c.4986+6T>C rs80358086) and the BRCA2 (c.6445_6446delAT rs80359592) Genes for Breast Cancer Prevention in Burkina Faso
por: Kiendrebeogo, Isabelle T, et al.
Publicado: (2022)

Clinical Characteristics of Ovarian Cancer Classified by BRCA1, BRCA2, and RAD51C Status
por: Cunningham, J. M., et al.
Publicado: (2014)

Medium-sized deletion in the BRCA1 gene: Limitations of Sanger sequencing and MLPA analyses
por: Herman, Sandra, et al.
Publicado: (2012)

BRCA Genetic Screening in Middle Eastern and North African: Mutational Spectrum and Founder BRCA1 Mutation (c.798_799delTT) in North African
por: Laraqui, Abdelilah, et al.
Publicado: (2015)

BRCA1, BRCA2 and PALB2 mutations and CHEK2 c.1100delC in different South African ethnic groups diagnosed with premenopausal and/or triple negative breast cancer
por: Francies, F. Z., et al.
Publicado: (2015)

Comprehensive clinical characterization of patients with BRCA1: c.5017_5019del germline variant
por: Bang, Yoon Ju, et al.
Publicado: (2022)

BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers
por: Maxwell, Kara N., et al.
Publicado: (2017)

Prediction of the functional impact of missense variants in BRCA1 and BRCA2 with BRCA-ML
por: Hart, Steven N., et al.
Publicado: (2020)

Autoimmune response to PARP and BRCA1/BRCA2 in cancer
por: Zhu, Qing, et al.
Publicado: (2015)

The Features of BRCA1 and BRCA2 Germline Mutations in Hakka Ovarian Cancer Patients: BRCA1 C.536 A>T Maybe a Founder Mutation in This Population
por: Luo, Yu, et al.
Publicado: (2022)

New Insights Into c.815_824dup Pathogenic Variant of BRCA1 in Inherited Breast Cancer: A Founder Mutation of West African Origin
por: Diop, Jean Pascal Demba, et al.
Publicado: (2022)

DCIS in BRCA1 and BRCA2 mutation carriers: prevalence, phenotype, and expression of oncodrivers C-MET and HER3
por: Yang, Rachel L., et al.
Publicado: (2015)

Identifying the BRCA1 c.-107A > T variant in Dutch patients with a tumor BRCA1 promoter hypermethylation
por: de Jong, Vincent M. T., et al.
Publicado: (2022)

The highest frequency of BRCA1 c.3700_3704del detected among Albanians from Kosovo
por: Kostovska, Ivana Maleva, et al.
Publicado: (2022)

Epistatic Relationships in the BRCA1-BRCA2 Pathway
por: Scully, Ralph
Publicado: (2011)

A model of the BRCA1/BRCA2 network
por: Pujana, MA, et al.
Publicado: (2005)

Molecular Trajectory of BRCA1 and BRCA2 Mutations
por: Hatano, Yuichiro, et al.
Publicado: (2020)

Evaluation of BRCA1 and BRCA2 as Indicators of Response to Immune Checkpoint Inhibitors
por: Zhou, Zhijun, et al.
Publicado: (2021)

BRCA1 c.4987-3C>G is a pathogenic mutation
por: Brandão, Rita D., et al.
Publicado: (2011)

Characterization of Synonymous BRCA1:c.132C>T as a Pathogenic Variant
por: Li, Jun, et al.
Publicado: (2022)

Multifactorial Likelihood Assessment of BRCA1 and BRCA2 Missense Variants Confirms That BRCA1:c.122A>G(p.His41Arg) Is a Pathogenic Mutation
por: Whiley, Phillip J., et al.
Publicado: (2014)

Identification of the core motif of the BRCA2 C-terminal RAD51-binding domain by comparing canine and human BRCA2
por: YOSHIKAWA, Yasunaga, et al.
Publicado: (2021)

Absence of 185delAG mutation of the BRCA1 gene and 6174delT mutation of the BRCA2 gene in Ashkenazi Jewish men with prostate cancer.
por: Lehrer, S., et al.
Publicado: (1998)

BRCA1 and BRCA2 mutations in Scotland and Northern Ireland
Publicado: (2003)

Clinical significance of large rearrangements in BRCA1 and BRCA2
por: Judkins, Thaddeus, et al.
Publicado: (2012)

The germline mutational landscape of BRCA1 and BRCA2 in Brazil
por: Palmero, Edenir Inêz, et al.
Publicado: (2018)

BRCA1 and BRCA2 Tumor Suppressor Function in Meiosis
por: Li, Qianyan, et al.
Publicado: (2021)

Prediction of carrying a BRCA1 or BRCA2 mutation
por: Lee, Kyung-Hun
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_h6ct62v1cljg4vlq7d3g1m06q3